Pharma BD Deal Intelligence
Jazz Pharmaceuticals' $7.2B acquisition of GW Pharmaceuticals landed the company its blockbuster: Epidiolex, the first FDA-approved cannabidiol drug, treating epilepsy. The deal diversified Jazz well beyond its sleep-disorder roots and paid off commercially, though it came at a steep multiple for a single-asset target.
Jazz Pharmaceuticals' acquisition of GW Pharmaceuticals closes, creating an innovative, high-growth global biopharma leader with a diversified portfolio…
Jazz acquired GW Pharmaceuticals for $7.2B for Epidiolex (cannabidiol) for epilepsy.
Epidiolex/Epidyolex achieved blockbuster status in 2025 with net product sales increasing 9% to $1.1 billion in 2025.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Jazz acquired GW Pharmaceuticals for $7.2B for Epidiolex (cannabidiol) for epilepsy.
3.4M US cases/yr · $8.5B Global Epilepsy Market (2024)
Treatment-resistant epilepsy affects approximately 30% of epilepsy patients who do not respond adequately to two or more antiseizure medications. Epidiolex (cannabidiol) was the first FDA-approved CBD-based medicine, specifically for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Epidiolex reached ~$510M in 2020 sales growing 70%+ YoY. Jazz expanded label indications and pursued nabiximols for MS spasticity. The cannabinoid science platform represents a unique differentiated approach in neurology.
Jazz announced GW acquisition to diversify beyond sleep and oncology. Part of Jazz Pharmaceuticals PLC's $7.2B deal to acquire GW Pharmaceuticals.
Jazz acquired GW at $220/ADS, gaining Epidiolex for epilepsy and cannabinoid R&D platform.
Epidiolex sales grew 15% YoY to $972M, approaching blockbuster status. Reflects financial performance following Jazz Pharmaceuticals PLC's $7.2B acquisition of GW Pharmaceuticals.
Jazz confirmed blockbuster trajectory for Epidiolex exceeding $1B in 2025. Part of Jazz Pharmaceuticals PLC's $7.2B deal to acquire GW Pharmaceuticals.
Epidiolex/Epidyolex reached blockbuster status with FY2025 net product sales of $1.1B, up 9% YoY, confirming the commercial-success thesis of Jazz's $7.2B GW acquisition. Approved in 35+ countries for Lennox-Gastaut, Dravet, and tuberous sclerosis complex.
Strong Commercial Success. Assessment of Jazz Pharmaceuticals PLC's $7.2B acquisition of GW Pharmaceuticals and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Jazz Pharmaceuticals PLC / GW Pharmaceuticals (this deal) | 2021 | $7.2B | 77 |
| Jazz Pharmaceuticals PLC / Celator Pharmaceuticals | 2016 | $1.5B | 73 |
| Jazz Pharmaceuticals PLC / AbCellera Biologics Inc. | 2026 | $848M | 50 |
| Jazz Pharmaceuticals PLC / Actio Biosciences, Inc. | 2026 | $1.3B | — |
| Jazz Pharmaceuticals PLC / Chimerix, Inc. | 2025 | $935M | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
← Browse all deals · How we score deals
More: 2021 deals · Jazz Pharmaceuticals PLC deals · Neurology deals